Naimish Patel, M.D. has served as Chief Medical Officer at CRISPR Therapeutics since May 2024, where he oversees a clinical portfolio spanning in vivo gene editing, allogeneic cell therapy, and RNA-based therapeutics. Prior to CRISPR, Naimish was at Sanofi, most recently as Global Development Therapeutic Area Head of Immunology and Inflammation. Before that role, he

Mr. Garcia has served as President, Chief Executive Officer, and member of the Board of Directors of Dianthus Therapeutics (Nasdaq: DNTH) since November 2021. He joined Dianthus prior to the company’s Series A financing and has led its transformation into a publicly traded, clinical-stage company with three product candidates in development and more than $1.6

Colin Bond has been a member of our board of directors since November 2024. Mr. Bond served as Chief Financial Officer at Sandoz, where he successfully led the spin-out of the company from Novartis. Previously, he was Chief Financial Officer at Vifor Pharma where he was instrumental in the separation of Galenica from Vifor Pharma

David R. Epstein has been a member of our board of directors since July, 2024. Mr. Epstein currently serves as Chief Executive Officer and Chairman of the Board of Directors of Ottimo Pharma Limited and is the former Chief Executive Officer and Director of Seagen, Inc. (formerly Nasdaq: SGEN), from November 2022 until Seagen’s acquisition

Felice Verduyn—van Weegen has been a member of our board of directors since October 2023. Ms. Verduyn—van Weegen has been a Partner at EQT Life Sciences, or EQT, a healthcare investment company, since July 2022. Ms. Verduyn—van Weegen worked for EQT’s predecessor, LSP Advisory B.V., or LSP, from March 2015 until July 2022. Prior to

Angelika Jahreis has been a member of our board of directors since October 2023. Ms. Jahreis has been the Senior Vice President, Global Head Immunology and Clinical Development Excellence at Novartis AG (NYSE: NVS), or Novartis, since January 2022 and the Global Head Development Unit Immunology, Hepatology & Dermatology at Novartis since September 2020. Prior

Ohad Hammer has been a member of our board of directors since April 2019. Mr. Hammer has been a Partner at Pontifax Venture Capital, or Pontifax, since January 2013. He also serves on the board of several of Pontifax’ portfolio companies including Step Pharma SAS since March 2021 and ADCendo ApS since April 2023. Mr.